This website uses cookies that help the website function and that help us understand how you interact with it. Please read our privacy policy for more information.
David F. Arons, JD President & Chief Executive Officer
David Arons is the President & Chief Executive Officer of the National Brain Tumor Society (NBTS). In his current role, David provides leadership and management for NBTS and its venture philanthropy affiliate, the Brain Tumor Investment Fund. Fighting cancer is personal to David as he lost his father to cancer as a teenager. Prior to joining NBTS, he served in leadership and external positions at the American Cancer Society in Minnesota, co-founded the Center for Lobbying in the Public Interest, and worked at Independent Sector in Washington, D.C. As a litigation attorney, he previously represented patients facing disabilities and serious health conditions. He is the author of several books, including “Power in Policy: A Funder’s Guide to Advocacy and Civic Participation,” “Strengthening Nonprofit Advocacy,” and “A Voice for Nonprofits.” David has served on the National Cancer Institute’s Council of Research Advocates and Clinical Trials Advisory Committee. In 2016, David was named to the Blue Ribbon Panel of experts selected to help advise the National Cancer Moonshot, led by former Vice President, now President Biden.
Ashley Brennan Chief Development Officer
Ashley Brennan, Chief Development Officer, oversees NBTS’s national development team and strategy. She manages a diverse fundraising portfolio, inclusive of a nationwide peer-to-peer program, Gray Nation Endurance, annual fund, major gifts, planned giving, and our corporate and foundation partnership program. Under Ashley’s leadership and team management, NBTS fundraising programs have expanded into multiple new regions, and our optimized virtual donor experience has resulted in revenue growth and the improvement of community connections. Before joining NBTS, Ashley served as a director for the Leukemia & Lymphoma Society, overseeing both internal and third-party special events, signature fundraising campaigns, and the stewardship and management of key individual and corporate donors and board member relations.
Katie Germain Chief Marketing and Communications Officer
Katie Germain is the Chief Marketing and Communications Officer at the National Brain Tumor Society. Prior to leading marketing and communications efforts for NBTS, Katie oversaw the digital marketing strategy and systems for Rutgers University Foundation for ten years, serving as lead strategist on major fundraising and engagement campaigns, including Rutgers Giving Day, Giving Tuesday, and the Hall of Distinguished Alumni Awards Gala. She previously held communications roles at Peddie School, Saint Peter’s University, and the National Center for Learning Disabilities.
Gary Heimberg, JD Vice President & Counsel, Government Relations
Gary Heimberg is Vice President & Counsel, Government Relations at the National Brain Tumor Society. In this role, Gary leads and manages relationships with elected and appointed officials, advances NBTS’s public policy agenda, and oversees a robust and inclusive volunteer advocacy program. Before joining NBTS, Gary was Of Counsel in the Public Policy and Government Affairs group at Covington & Burling, LLP in Washington, DC. Prior to Covington, Gary served as Director of Federal Government Relations for GlaxoSmithKline. Earlier in his career, he was a professional staff member for the U.S. Senate Health Education, Labor & Pensions (HELP) Committee and a floor assistant for the Senate Majority Secretary. Gary also served as an adjunct professor at the George Washington University Law School. As a volunteer, Gary is deeply committed to the mission of finding a cure to brain tumors and is active in the Race for Hope DC.
John Higgins Managing Director, Brain Tumor Investment Fund
John Higgins is Managing Director at the Brain Tumor Investment Fund, the venture philanthropy arm of NBTS. John’s career spans 30 years in biopharma commercialization and business development within both large and emerging companies, most recently as VP Commercial and Corporate Development at Istari Oncology, a startup focused on glioblastoma and other solid tumors. John’s role in BTIF leverages NBTS internal expertise and external networks to identify, evaluate, and invest in promising biopharma, diagnostic, and medical device companies developing advances for brain tumors.
Rich Lescarbeau, MBA, CPA Vice President, Finance and Accounting
Rich Lescarbeau is the VP of Finance and Accounting at the National Brain Tumor Society. Rich has more than 15 years experience as a finance and accounting professional with significant experience leading financial, operational and organizational performance in nonprofit organizations. Rich has expertise in financial management and reporting, treasury, investment and cash management, budgeting and forecasting, strategic planning, financial planning and analysis, grant and contract administration and demonstrated success in providing clear, consistent leadership working with senior leadership and Boards of Directors.
Marisa Petrillo Chief Operating Officer
Marisa Petrillo is the Chief Operating Officer at the National Brain Tumor Society. Marisa brings more than two decades of experience to her role as a strategic business partner providing guidance on HR policies and procedures, performance management, payroll and benefits administration, employee onboarding and integration, recognition and employee relations, talent acquisition, cybersecurity, IT & systems management. Marisa is committed to working with leadership and staff to build a diverse, equitable, and inclusive workplace. She has extensive experience in the nonprofit, financial, and creative services sector. Marisa is a member of the Society for Human Resource Management and the Human Capital Institute.
Jenna Tozzi, RN Senior Director of Community
Jenna Tozzi is the Senior Director of Community at NBTS, bringing 15 years of experience as a multi-state registered nurse dedicated to the rare disease and oncology communities. Her career began in pediatrics, eventually leading to her role as a Director of Nursing at a special needs school, where she provided essential education and connected families facing complex medical challenges with vital community resources.
Over the past 9 years, Jenna has developed nationwide navigation programs aimed at expanding access to clinical trials and improving patient outcomes.Having personally navigated life with a rare disease, Jenna brings a unique ability to anticipate the needs of others, helping patients and families make informed decisions with confidence. She is passionate about empowering patients to overcome barriers to care while ensuring their voices are heard throughout their healthcare journey.
Kimberly M. Wallgren Executive Director of the CERN Foundation, a program of the National Brain Tumor Society
Kimberly M. Wallgren is the Executive Director of the CERN Foundation, a program of the National Brain Tumor Society. Under Kim’s leadership, the CERN Foundation has built the leading ependymoma tumor-focused community in the United States and globally, raising public awareness, advancing medical research, and providing support and advocacy for this often underserved disease affecting children and adults.
Bringing nearly fifteen years of experience interacting with patients and families, Kim is passionate about the individual experience of a CNS tumor diagnosis and seeks to influence outcomes by providing direction and education at critical points of the journey. Kim is committed to collaboration between all stakeholders, and she bridges gaps between industry leaders and the patient community.
Board of Directors
Officers
Edjah Nduom, MD Chair
Edjah Nduom is the Chair of National Brain Tumor Society Board of Directors. Edjah holds the Daniel Louis Barrow Endowed Chair in Neurosurgery and is an associate professor in the Department of Neurosurgery at Emory University School of Medicine. A fellowship-trained and board certified neurosurgical oncologist, Dr. Nduom’s clinical specialty is the surgical management of brain and spinal cord tumors. He holds numerous positions in national and international medical societies. Dr. Nduom received his MD from University of Pennsylvania and his residency in Neurosurgery at Emory University. He completed a Research Fellowship in Neurosurgical Oncology in the Surgical Neurology Branch of the National Institute of Neurological Disorders and Stroke, and an additional Neurosurgical Oncology Fellowship at MD Anderson Cancer Center.
Erica Birke Vice Chair
Erica Birke is the Vice Chair of the National Brain Tumor Society Board of Directors. She is also the Head of Institutional and Asset Management Marketing at Fidelity Investments. Prior to her current role, Erica was the Head of Communications for Fidelity Institutional, a division of Fidelity Investments and has served other communications roles within the company since 2009. She has a Bachelor of Arts in political science and English from James Madison University. Erica joined the Board in honor of her father who lost his life to glioblastoma, as well as others in her family who have been affected by the disease.
Mil Parekh Treasurer
Mil Parekh is the Treasurer of the National Brain Tumor Society Board of Directors. He is a Senior Vice President, Portfolio Management Director, and Family Wealth Advisor at Morgan Stanley. Mil has more than 17 years of wealth management experience, and has dedicated his career to providing customized advice and investment solutions to highly successful individuals, families, and business leaders. Mil earned a degree in Finance from George Washington University and has been recognized as a Forbes Best in State Advisor, recognizing the top financial advisors in the state of Virginia, for 2019, 2022, and 2023.
Leah Recht, JD Clerk
Leah Recht is the Clerk of the National Brain Tumor Society Board of Directors. Leah Recht is a partner at Orrick and a member of Orrick’s M&A and Private Equity Group. Her practice focuses on advising private equity funds and their portfolio companies in all aspects of their business. Leah advises clients across a wide range of industries, including tech, food and drug, consulting services, retail, education, manufacturing, insurance, printing and transportation. Leah earned her JD from Georgetown University and was recognized in 2018 and 2019 as a Super Lawyers “Rising Star” for business and corporate law.
Board Members
Co-Founder: G. Bonnie Feldman The Brain Tumor Society
Co-Founder: Walter & Ellen Newman and David & Nora Plant National Brain Tumor Foundation
Emeritus Board Members
Dave Brown
Rob Burger
Michael Corkin
Rob Corrao
Dave Donabedian
Sarah Durham
John Frishkopf
Eva Galanis, MD
Richard Genderson
Ken Grey
Steve Karol
Sheila Killeen
Jeffrey Kolodin (deceased)
Ryan Lang
Michael Nathanson, JD, LLM
Chandri Navarro
Eric Olson, PhD
Susan Pannullo, MD
Thomas Roloff
Dennis Roth
Steve Sadler
Liz Salmi
Cord Schlobohm, DMD
Rabbi Eric B. Wisnia
Charles B. Wilson, MD (deceased)
Salo Zelermyer, JD
Scientific Medical Advisory Council
Nduka Amankulor, MD, Neurosurgeon, Penn Medicine
Sonikpreet Aulakh, MD, Neuro-Oncologist, West Virginia Cancer Institute
Adrienne Boire, MD, PhD, Neurologist and Neuro-Oncologist, Memorial Sloan Kettering Cancer Center
Anthony Chalmers, Neuro-oncologist, University of Glasgow
Mariella Filbin, MD, PhD, Pediatric Neuro-Oncologist, Boston Children’s Hospital; Co-Director for Research, Dana-Farber Cancer Institute; Co-Director, Brain Tumor Center of Excellence; Associate Professor, Harvard Medical School
Mark Gilbert, MD, Scientist Emeritus, National Cancer Institute
Michael Lim, MD, Neurosurgeon, Stanford Medicine
Nancy Lin, MD, Medical Oncologist, Dana-Farber Cancer Institute
Paul Salomon Mischel, MD, Professor, Stanford Medicine
Eric Olson, PhD
Vinay Puduvalli, MD, Neuro-Oncologist, The University of Texas MD Anderson Cancer Center
Joachim Reischl, PhD, Vice President, External Innovation Diagnostics, Danaher Corporation
Yash Thukral, JD, CEO of White Lion GBM Innovation Fund
Julia Veitinger, MPH, MBA, Patient Advocate
Timothy A. Yap, MBBS, PhD, FRCP, Head of Clinical Development and Vice President, Therapeutics Discovery Division; Professor, Department of Investigational Cancer Therapeutics (Phase I Program); The University of Texas MD Anderson Cancer Center
Stergios Zacharoulis, MD, Pediatric Neuro-Oncologist, Columbia University Medical Center